Logo image of CDNA

CAREDX INC (CDNA) Stock Price, Forecast & Analysis

USA - NASDAQ:CDNA - US14167L1035 - Common Stock

14.52 USD
-0.25 (-1.69%)
Last: 11/4/2025, 8:06:51 PM
16.25 USD
+1.73 (+11.91%)
Pre-Market: 11/5/2025, 8:31:38 AM

CDNA Key Statistics, Chart & Performance

Key Statistics
Market Cap772.90M
Revenue(TTM)333.79M
Net Income(TTM)51.68M
Shares53.23M
Float51.28M
52 Week High26.37
52 Week Low10.96
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.65
PE22.34
Fwd PE17.79
Earnings (Next)02-24 2026-02-24/amc
IPO2014-07-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CDNA short term performance overview.The bars show the price performance of CDNA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15 20

CDNA long term performance overview.The bars show the price performance of CDNA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of CDNA is 14.52 USD. In the past month the price decreased by -1.02%. In the past year, price decreased by -38.6%.

CAREDX INC / CDNA Daily stock chart

CDNA Latest News, Press Relases and Analysis

CDNA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 22.85 381.38B
AMGN AMGEN INC 13.57 159.73B
GILD GILEAD SCIENCES INC 15.02 152.62B
VRTX VERTEX PHARMACEUTICALS INC 24.29 108.11B
REGN REGENERON PHARMACEUTICALS 13.95 66.56B
ALNY ALNYLAM PHARMACEUTICALS INC 830.33 55.51B
ARGX ARGENX SE - ADR 62 51.19B
INSM INSMED INC N/A 38.63B
ONC BEONE MEDICINES LTD-ADR 5 33.96B
NTRA NATERA INC N/A 26.96B
BNTX BIONTECH SE-ADR N/A 25.20B
BIIB BIOGEN INC 8.92 21.89B

About CDNA

Company Profile

CDNA logo image CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.

Company Info

CAREDX INC

8000 Marina Blvd, 4th Floor

Brisbane California CALIFORNIA 94080 US

CEO: Reginald Seeto

Employees: 644

CDNA Company Website

CDNA Investor Relations

Phone: 14152872300

CAREDX INC / CDNA FAQ

What does CAREDX INC do?

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.


Can you provide the latest stock price for CAREDX INC?

The current stock price of CDNA is 14.52 USD. The price decreased by -1.69% in the last trading session.


Does CDNA stock pay dividends?

CDNA does not pay a dividend.


What is the ChartMill rating of CAREDX INC stock?

CDNA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Can you provide the sector and industry classification for CAREDX INC?

CAREDX INC (CDNA) operates in the Health Care sector and the Biotechnology industry.


What is CAREDX INC worth?

CAREDX INC (CDNA) has a market capitalization of 772.90M USD. This makes CDNA a Small Cap stock.


What is the Short Interest ratio of CAREDX INC (CDNA) stock?

The outstanding short interest for CAREDX INC (CDNA) is 11.79% of its float.


CDNA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to CDNA. When comparing the yearly performance of all stocks, CDNA is a bad performer in the overall market: 76.32% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CDNA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to CDNA. CDNA has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDNA Financial Highlights

Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.65. The EPS increased by 242.11% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.16%
ROA 11.63%
ROE 15.79%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%100%
Sales Q2Q%20.72%
EPS 1Y (TTM)242.11%
Revenue 1Y (TTM)19.07%

CDNA Forecast & Estimates

15 analysts have analysed CDNA and the average price target is 22.95 USD. This implies a price increase of 58.06% is expected in the next year compared to the current price of 14.52.

For the next year, analysts expect an EPS growth of 1.06% and a revenue growth 11.33% for CDNA


Analysts
Analysts80
Price Target22.95 (58.06%)
EPS Next Y1.06%
Revenue Next Year11.33%

CDNA Ownership

Ownership
Inst Owners102.13%
Ins Owners2.37%
Short Float %11.79%
Short Ratio4.56